SK bioscience and MSD Advance Ebola Vaccine Development with CEPI Support

SK bioscience has announced significant progress in the development of a Zaire ebolavirus vaccine through a new collaboration supported by the Coalition for Epidemic Preparedness Innovations (CEPI). This initiative follows a funding agreement between CEPI and the global pharmaceutical company MSD, which will allocate up to USD 30 million to advance vaccine development efforts. The funding will be distributed among development partners, including SK bioscience and Hilleman Laboratories, a joint venture between MSD and the Wellcome Trust.

Collaboration to Enhance Vaccine Manufacturing

The collaboration aims to enhance the existing manufacturing process of the Zaire ebolavirus vaccine, which is currently complicated by the need for ultra-low temperature storage. These stringent requirements create logistical challenges, particularly in remote and low-resource regions where Ebola outbreaks frequently occur. The project will focus on improving manufacturing yield and increasing the vaccine’s thermostability, making it more affordable, accessible, and sustainable.

Hilleman Laboratories will lead the clinical development of the updated vaccine. Meanwhile, SK bioscience, in partnership with IDT Biologika, will work on developing the updated drug substance manufacturing process and the associated drug product. As a key implementation partner in this public health initiative, SK bioscience plans to utilize its manufacturing expertise to enhance vaccine availability in low- and middle-income countries.

The Zaire ebolavirus is responsible for frequent Ebola outbreaks, with survival rates hovering around 50%. Recent outbreaks in the Democratic Republic of the Congo and other regions highlight the persistent threat posed by the virus, especially in areas with limited healthcare access.

Leadership Perspectives on Global Health Collaboration

Dr. Richard Hatchett, CEO of CEPI, expressed optimism about the project, stating, “In a single decade, the world has transformed Ebola from a global emergency to a disease that can be stopped in its tracks. CEPI’s support will help enable a sustainable supply of MSD’s Zaire ebolavirus vaccine for years to come at a more affordable price.” He emphasized the importance of collaboration in strengthening defenses against one of the deadliest pathogens known to humanity.

Jaeyong Ahn, CEO of SK bioscience, echoed this sentiment, saying, “Addressing deadly infectious diseases such as Ebola requires strong global collaboration. Through this CEPI-supported partnership, SK bioscience will continue to play a critical role in improving vaccine manufacturing and supply.” Ahn emphasized the company’s commitment to global health preparedness and its ongoing partnerships with organizations like CEPI, the Gates Foundation, and the International Vaccine Institute.

SK bioscience is dedicated to developing and manufacturing vaccines to promote equitable access globally. This initiative marks another step in the company’s efforts to address public health challenges through innovative solutions. Their collaborative approach aims to leverage cutting-edge technologies to enhance human health from prevention to cure.

As the world continues to face the challenges of infectious diseases, initiatives like this one are crucial in ensuring that effective vaccines are accessible to those in need, particularly in vulnerable regions. The collaboration between SK bioscience, MSD, and Hilleman Laboratories represents a significant step forward in the fight against Ebola.